


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Compounds of the formula I



in which

R denotes Hal,  $-C\equiv C-H$ ,  $-C\equiv C-A$  or OA,


R<sup>1</sup> denotes H, =O, Hal, A, OH, OA, A-COO-, Ph-(CH<sub>2</sub>)<sub>n</sub>-COO-, cycloalkyl-(CH<sub>2</sub>)<sub>n</sub>-COO-, A-CONH-, A-CONA-, Ph-CONA-, N<sub>3</sub>, NH<sub>2</sub>, NO<sub>2</sub>, CN, COOH, COOA, CONH<sub>2</sub>, CONHA, CON(A)<sub>2</sub>, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA or =CF<sub>2</sub>,

R<sup>2</sup> denotes H or A,

Ph denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, OH or Hal,

R<sup>3</sup> denotes H, Hal or A,

R<sup>4</sup> denotes  $-C_6H_4-(CH_2)_n-NR^5R^{5'}$ ,  $-C(=NR^5)NR^5R^{5'}$ ,



R<sup>5</sup>, R<sup>5'</sup> each, independently of one another, denote H or A,

A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,


n denotes 0, 1, 2 or 3,  
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Original) Compounds according to Claim 1, in which  
R denotes Hal or  $\text{-C}\equiv\text{C-H}$ ,  
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.
3. (Currently Amended) Compounds according to Claim 1 ~~or 2~~, in which  
 $\text{R}^1$  denotes H, =O, Hal, A, OH or OA,  
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.
4. (Currently Amended) Compounds according to ~~one or more of Claims 1-3~~  
Claim 1, in which  
 $\text{R}^1$  denotes OH or OA,  
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.
5. (Currently Amended) Compounds according to ~~one or more of Claims 1-4~~  
Claim 1, in which  
 $\text{R}^3$  denotes H or Hal,  
and the pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.
6. (Currently Amended) Compounds according to ~~one or more of Claims 1-5~~  
Claim 1, in which  
 $\text{R}^5$ ,  $\text{R}^{5'}$  each, independently of one another, denote H or alkyl having 1, 2, 3, 4,  
5 or 6 C atoms,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

7. (Original) Compounds according to Claim 1, in which

- R denotes Hal or  $-C\equiv C-H$ ,  
 $R^1$  denotes OH or OA  
 $R^2$  denotes H or A,  
 $R^3$  denotes H or Hal,  
 $R^4$  denotes  $-C_6H_4-(CH_2)_n-NR^5R^{5'}$ ,  $-C(=NR^5)NR^4R^{5'}$ ,



$R^5$ ,  $R^{5'}$  each, independently of one another, denote H or A,

- A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,  
Hal denotes F, Cl, Br or I,  
n denotes 0, 1, 2 or 3,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

8. (Original) Compounds according to Claim 1 selected from the group

N-1-[(4-chlorophenyl)]-N-2-{[4-(2-{dimethylaminomethyl}phenyl)-phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-{[4-(2-{dimethylaminomethyl}phenyl)-phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-{[2-fluoro-4-(2-{dimethylaminomethyl}phenyl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-{[2-fluoro-4-(2-{dimethylaminomethyl}phenyl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(4-(2-dimethylaminomethylimidazol-1-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(4-(2-dimethylaminomethyl-imidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(2-dimethylaminomethyl-imidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(2-dimethylamino-methylimidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(*N,N*-dimethylamidino)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(*N,N*-dimethylamidino)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,


N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

9. (Currently Amended) Process for the preparation of compounds of the formula I according to ~~Claims 1-8~~ Claim 1 and pharmaceutically usable derivatives,

solvates, salts and stereoisomers thereof, characterised in that


a) a compound of the formula II



in which R has the meaning indicated in Claim 1,

is reacted with a chloroformate derivative to give an intermediate carbamate derivative,

which is subsequently reacted with a compound of the formula III




in which

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> have the meaning indicated in Claim 1,

or

b) a compound of the formula III

is reacted with a compound of the formula IV




in which

R has the meaning indicated in Claim 1,


or

c) a compound of the formula V



in which  $R^3$  and  $R^4$  have the meaning indicated in Claim 1,

is reacted with a compound of the formula VI



in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group  
and

$R$ ,  $R^1$  and  $R^2$  have the meanings indicated in Claim 1,

and/or

a base or acid of the formula I is converted into one of its salts.

10. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 as inhibitors of coagulation factor Xa.
11. (Currently Amended) Compounds of the formula I according to ~~one or more of~~

~~Claims 1 to 9~~ Claim 1 as inhibitors of coagulation factor VIIa.

12. (Currently Amended) Medicaments comprising at least one compound of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
13. (Currently Amended) Medicaments comprising at least one compound of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
14. (Currently Amended) Use of compounds according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tinnitus, tumours, tumour diseases and/or tumour metastases.
15. (Currently Amended) Set (kit) consisting of separate packs of
  - (a) an effective amount of a compound of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,
  - and
  - (b) an effective amount of a further medicament active ingredient.
16. (Currently Amended) Use of compounds of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or pharmaceutically usable derivatives,

solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,

for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tinnitus, tumours, tumour diseases and/or tumour metastases,

in combination with at least one further medicament active ingredient.